Table 4.
Major adverse cardiac events and side effects during follow-up
| Ticagrelor group (n=38) | Clopidogrel group (n=36) | P | |
|---|---|---|---|
| Cardiac death-n. (%) | 0 (0) | (0) | - |
| Heart Failure-n. (%) | 0 (0) | (0) | - |
| Remyocardial Infarction-n. (%) | 0 (0) | 1 (2.7) | 0.486 |
| Targeted Vessel Reconstruction-n. (%) | 0 (0) | (0) | - |
| Cardiac Readmission-n. (%) | 2 (5.3) | 4 (11.1) | 0.418 |
| TIMI bleeding-n. (%) | |||
| Major bleeding | 0 (0) | (0) | - |
| Minor bleeding | 4 (10.5) | 3 (8.3) | 1.000 |
| Minimal bleeding | 1 (2.6) | 1 (2.7) | 1.000 |
| Dyspnea-n. (%) | 4 (10.5) | 0 (0) | 0.116 |
| Bradycardia-n. (%) | 1 (2.6) | 0 (0) | 1.000 |